46,053 Shares in Bausch + Lomb Corporation $BLCO Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new position in Bausch + Lomb Corporation (NYSE:BLCO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 46,053 shares of the company’s stock, valued at approximately $787,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BLCO. Glenview Capital Management LLC lifted its holdings in Bausch + Lomb by 210.8% in the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the last quarter. Davidson Kempner Capital Management LP acquired a new stake in Bausch + Lomb in the 3rd quarter worth approximately $14,776,000. Oaktree Capital Management LP lifted its holdings in Bausch + Lomb by 28.7% in the 3rd quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company’s stock worth $48,909,000 after purchasing an additional 724,194 shares during the last quarter. Woodline Partners LP lifted its holdings in Bausch + Lomb by 175.3% in the 3rd quarter. Woodline Partners LP now owns 861,053 shares of the company’s stock worth $12,976,000 after purchasing an additional 548,230 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Bausch + Lomb by 428.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock worth $4,345,000 after purchasing an additional 242,993 shares during the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BLCO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Bausch + Lomb in a report on Monday, April 20th. Citigroup set a $19.00 target price on Bausch + Lomb and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Wells Fargo & Company upped their price target on Bausch + Lomb from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. HC Wainwright upped their price target on Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Finally, Wall Street Zen upgraded Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.92.

Bausch + Lomb Stock Down 2.7%

Shares of BLCO stock opened at $15.23 on Thursday. Bausch + Lomb Corporation has a 12 month low of $11.44 and a 12 month high of $18.92. The firm has a market cap of $5.44 billion, a PE ratio of -24.57, a price-to-earnings-growth ratio of 0.48 and a beta of 0.58. The stock has a 50 day moving average of $16.01 and a 200-day moving average of $16.60. The company has a quick ratio of 0.99, a current ratio of 1.53 and a debt-to-equity ratio of 0.78.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 4.21%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.07) earnings per share. On average, equities analysts predict that Bausch + Lomb Corporation will post 0.82 EPS for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.